Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics

Bokemeyer B, Plachta-Danielzik S, Sobotzki C, Mohl W, Hoffstadt M, Krause T, Atreya R, Von Der Ohe M, Graefe U, Trentmann L, Eisold M, Linde A, Franzenburg S, Moser M, Hartmann P, Schreiber S (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Journal of Crohns & Colitis Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: S584-S584

Conference Proceedings Title: JOURNAL OF CROHNS & COLITIS

DOI: 10.1093/ecco-jcc/jjz203.854

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) Competence Network IBD DE Germany (DE) Gastroenterologische Gemeinschaftspraxis Minden DE Germany (DE)

How to cite

APA:

Bokemeyer, B., Plachta-Danielzik, S., Sobotzki, C., Mohl, W., Hoffstadt, M., Krause, T.,... Schreiber, S. (2020). Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics. In JOURNAL OF CROHNS & COLITIS (pp. S584-S584). OXFORD: OXFORD UNIV PRESS.

MLA:

Bokemeyer, B., et al. "Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics." Proceedings of the JOURNAL OF CROHNS & COLITIS OXFORD: OXFORD UNIV PRESS, 2020. S584-S584.

BibTeX: Download